Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554089 | 0.90 | BCL3 (0.75) | BCL3KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL17554018 | 0.89 | BCL3 (0.57) | BCL3KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL19348406 | 0.85 | BCL3 (0.78) | BCL3KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL30560633 | 0.85 | BCL3 (0.78) | BCL3KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL30560626 | 0.85 | BCL3 (0.74) | BCL3KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL17554039 | 0.85 | BCL3 (0.74) | BCL3KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL17554013 | 0.82 | ALDH1A1 (0.62) | BCL3KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL30560589 | 0.82 | BCL3 (0.63) | BCL3KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL17554147 | 0.82 | BCL3 (0.63) | BCL3KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL17554027 | 0.81 | ALDH1A1 (0.69) | BCL3ALDH1A1DRD2DRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | BCL3 1/4885KMT2A 3099/4885MEN1 2135/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | BCL3 1/4885KMT2A 2931/4885MEN1 2602/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | BCL3 1/4885KMT2A 2931/4885MEN1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.